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SUMMARY 
Background: Microalbuminuria is an early indicator of Diabetic nephropathy and cerebrovascular disease.  
Objective: To evaluate relationships between microalbuminuria and other predictors of morbidity and mortality in 
type 2 DM. 
Methods: Fifty type 2 diabetic subjects were recruited each for three groups separated by disease durations. Thirty 
non-diabetic subjects were recruited to control each group.  Urine albumin-to-creatinine ratio (ACR) was estimated. 
Fasting plasma glucose (FPG), serum creatinine, urea, total cholesterol (TC), triglycerides (TG), high- and low den-
sity lipoprotein (HDL, LDL) were measured.  
Results: The diabetics with longest disease duration of >10 years were the oldest (65.86±1.71), had highest systolic 
BP (147.12±3.39mmHg) and least BMI (27.20±0.71Kg/m2); they had poorest lipid control (TC:5.54±0.26mmol/L), 
though with the least TG (0.97±0.09mmol/L); they also had the most severe microalbuminuria (33.63±8.03g/L) and 
ACR (65.85±10.38mg/gm). Patients with diabetes of 5-10 years had the poorest glycaemic control:FPG-
7.82±0.47mmol/L; HbA1c-13.09±0.74%). Significant negative correlations exist between microalbuminuria, 
HBA1c(r=-2.28, p=0.028) and serum creatinine(r=-2.11,p=0.042) in patients with 5-10 years disease; a positive cor-
relation between the ACR and TC(r=1.00,p<0.01) in those with >10 years disease. In multivariate analysis, inde-
pendent predictors of microalbuminuria were disease duration (OR 2.2, p< 0.001); HBA1c (OR 7.3, p=0.02); 
LDL/HDL ratio (OR 13.4, p< 0.001).  
Conclusion: The severity and progression of albuminuria are associated with longer duration of diabetes and poor 
glycaemic control. Significant relationships exist between ACR and HBA1c, TC, HDL-C, TG, creatinine. Disease 
duration, ethnicity, HBA1c, TC, TG, HDL-C and LDL/HDL ratio are independent predictors of albuminuria. 
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INTRODUCTION 
The chronic hyperglycaemia of diabetes is associated 
with long-term damage, dysfunction and failure of vari-
ous organs, especially the eyes, kidneys, nerves, heart, 
and blood vessels. Diabetic nephropathy (DN) is an 
important and life-threatening microvascular complica-
tion of diabetes mellitus (DM). It is usually first mani-
fested as an increase in urinary albumin excretion 
(which could be microalbuminuria, defined as the uri-
nary excretion of albumin of 20-200 µg/min or 30-299 
mg/g of creatinine or macroalbuminuria, defined as uri-
nary albumin to creatinine ratio greater than 200 µg/min 
or ≥300 mg/gm of creatinine and <30mg/gm is nor-
mal.1,2 Macroalbuminuria is an overt clinical manifesta-
tion of renal dysfunction which could progress to renal 
failure.3 Microalbuminuria has been associated with an 
increased risk of Cardiovascular diseases (CVD) in pa-
tients with and without DM.4,7  
 
Therefore, in patients with DN, the increased cardiovas-
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Kidney Disease (CKD) are additive and increase as DN 
progresses.8 Without specific intervention, 20%-40% of 
patients with type 2 diabetes and microalbuminuria will 
progress to overt nephropathy and ultimately End Stage 
Renal Disease (ESRD).8 
 
Microalbuminuria is an indicator of the incipient phase 
of diabetic nephropathy in diabetes mellitus, and pro-
gressive albuminuria is a generally recognized criterion 
for determining the degree of diabetic nephropathy.5,8 If 
present, microalbuminuria identifies patients at risk for 
early cardiovascular death and progressive renal dis-
ease.  
 
Microalbuminuria also identifies patients who need 
more rigorous cardiovascular risk management, espe-
cially more intensive blood pressure control, (preferably 
below 130/80 mm Hg), and strict attention to glycaemic 
control and lipid levels.6,8  Consequently, identification 
of such patients for early commencement of appropriate 
therapeutic measures should be an important considera-
tion.7  Therapeutic approaches to enhance better blood 
pressure control and reduce microalbuminuria will like-
ly prove to be the most effective way to retard the pro-
gression of both renal and cardiovascular diseases or 
complications in patients with type 2 DM.7 
 
Despite the increased attention in various parts of the 
world on the role of the biochemical parameters in the 
disease progression and management of diabetes melli-
tus, there is still paucity of information on the inter-
relationship among these markers to one another and to 
presence of microvascular complications in Nigeria 
especially in relation to disease duration. The study was 
designed to determine the relationship between these 
biochemical parameters and disease duration (number of 
years with DM). Additionally we explored the associa-
tion between these parameters and microvascular com-
plications of DM. 
 
METHODS 
Study design and study population 
This study was designed as a cross sectional study. It 
was conducted over a period of 6 months at the Obafemi 
Awolowo University Teaching Hospitals Complex 
(OAUTHC) in Ile-Ife, South Western Nigeria.    
 
A total of 150 type 2 diabetics attending outpatient de-
partment of the diabetic clinics at OAUTHC were re-
cruited for this study. Fifty subjects were recruited for 
each of the three categories based on disease duration 
thus: 50 newly diagnosed; 50 who have been on therapy 
for 5-10 years; and 50 who have been on therapy for 
more than 10 years. Subjects were selected by simple 
random sampling method for each group. 
 
Those with history suggestive of a haemolytic disorder 
(like sickle cell anaemia) with shortened red blood cell 
survival, and subjects with non-diabetes-related condi-
tions that might increase microalbuminuria such as uri-
nary tract infection, haematuria, heart failure, febrile 
illness, severe hypertension, and vigorous exercise were 
excluded. All other subjects that satisfied the inclusion 
criteria consented and were thus consecutively recruited 
till sample size was achieved. 
 
 Thirty (30) age- and sex- matched non-diabetic subjects 
(members of staff of the hospital, relatives of patients 
and other volunteers), were recruited as control. Age, 
sex, disease duration, social status, economic and educa-
tion status, medical history and type of treatment, were 
obtained from patients’ records. All data were collected 
by Principal Investigator. Ethics and Research Commit-
tee of OAUTHC, Ile-Ife gave its approval (Protocol 
number ERC/2013/01/02) for the study to be conducted.  
 
Confidentiality: All information gathered in this study 
was stored in a personal computer, kept confidential and 
accessed only by authorized personnel.   
The sample size per group was statistically derived from 
the formula:                        
    n =Z2pq/d   by applying the index prevalence of 
2.2% of DM in the population at the time of study. The 
minimum required for each group was 33. 
 
Sample collection, laboratory methods and analysis 
12ml of fasting venous blood was collected from all 
patients. The collected blood was divided into:  
(i) EDTA bottles (2ml) and appropriately stored in 
a refrigerator at a temperature of 4-8°C until 
assayed for HBA1c levels within 7 days ac-
cording to HBA1c assay reagents manufactur-
ers specifications; 
(ii) Fluoride oxalate bottles (2ml) for fasting plama 
glucose estimation and the assay was done 
same day; 
(iii) 8ml into plain serum bottles and allowed for 
clotting and retraction. Sample was immediate-
ly centrifuged, separated and serum collected 
was stored and analysed the same day; or 
stored at -70oC until estimated for serum lipids, 
urea and creatinine, but all within the limit of 
sample storage and stability for all the analytes.  
 
Overnight urine sample for albumin and creatinine was 
collected into universal bottle. Urine albumin was esti-
mated in fresh urine while the creatinine sample was 
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Fasting plasma glucose (FPG) was determined by the 
glucose oxidase method9, serum creatinine by Jaffe ki-
netic method10, serum urea by urease enzyme method11, 
total cholesterol by the oxidase/peroxidase (CHOD-
POD) method12, triglycerides by the enzymatic GPO-
POD method13, high density lipoprotein by phospho-
tungstate precipitation and (CHOD-POD) method14, 
HbA1c by the cation exchange resin method15,16 and 
agglutination method17 was used to determine microal-
bumin levels in the urine sample. 
 
Fasting plasma glucose of 3-5mmol/L was defined as 
good glycaemic control, 5-8mmol/L as fair control and 
>8.0mmol/L as poor control. HBA1c of ≤6.5% defined 
good glycaemic control. HDL, Normal total cholesterol 
is taken as <5.2 mmol/L, low density lipoprotein <3.5 
mmol/L, triglyceride <1.7 mmol/L and high density 




The data collected was analysed using descriptive and 
inferential statistics. Continuous variables are given as 
mean (standard deviation, SD) and categorical variables 
as percentages. Analysis of Variance was used to com-
pare the means among groups. Paired Students T-tests  
were used to compare means of pairs of groups. Pearson 
moment correlation was done to determine the relation-
ship between the variables.  
 
Multiple linear regressions were then used to determine 
the predictors of different markers of nephropathy and 
other complications of DM. The level of significance 
was set at p ≤0.05. Statistical analyses were performed 
using the SPSS version 17 software package (SPSS Inc., 
Chicago, Illinois, USA). 
 
RESULTS 
Table 1 shows the age and anthropometric characteris-
tics of the three diabetic groups in comparison with the 
controls. Patients, who were diabetic for 10 years and 
above were the oldest, had highest systolic BP, but the 
least BMI than the rest of the groups.  
 
 
Table 1 Age and anthropometric characteristics:  comparison of the diabetic groups with control group  
Measured Variables Control (n=30) Newly Diagnosed (n=50) 
5-10 years DM  
 (n=50) 
>10 years DM 
(n=50) 
  Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
Age (years) 53.77±2.02 57.96±1.24 62.64±1.22 65.86±1.71 
p value (Control vs Group)   p=0.07 p<0.01 p<0.01 
 
Weight(kg) 71.37±2.31 73.44±1.67 73.1±1.82 70.52±1.73 











p value (Control vs Group)   p=0.17 p<0.01 p=0.151 
 
BMI(kg/m2) 28.58±0.97 28.44±0.70 27.55±0.63 27.20±0.71 
p value (Control vs Group)   p=0.9 p=0.3 p=0.251 
 
Systolic BP(mmHg) 125.63±4.01 127.36±2.30 137.50±2.85 147.12±3.39 
p value (Control vs Group)   p=0.69 p=0.016 p<0.01 
 
Diastolic BP(mmHg) 79.80±2.54 77.20±1.03 79.82±1.93 78.64±1.94 
p value (Control vs Group)   p=0.28 p=0.99 p=0.717 
 
Waist Circumference(cm) 93.23±2.84 94.62±1.88 94.82±1.98 98.10±1.58 
p value (Control vs Group)   p=0.67 p=0.64 p=0.11 
 
Abdominal Circumference 94.00±2.33 97.48±1.88 99.34±1.92 97.03±1.39 
p value (Control vs Group)   p=0.25 p=0.086 p=0.23 
 
Table 2 shows the biochemical characteristic of the var-
ious diabetic groups and the controls. Patients with dia-
betes duration of 5-10 years had the poorest glycaemic 
control as reflected in their highest FPG and HbA1c. 
Patients with disease duration of more than 10 years had 
the poorest lipid control, the highest level of microal-
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Table 2 Biochemical characteristics: comparisons of the diabetic groups with the control group 
Measured Variables Control (n=30) 
Newly Diagnosed 
(n=50) 
5-10 years    DM  
 (n=50) >10 years DM     (n=50) 
  Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
FPG (mmol/l) 4.16±0.10 6.53±0.47 7.82±0.47 7.37±0.40 
p value (Control vs Group)   p<0.001 p<0.01 p<0.01 
HBA1C (%) 5.56±0.17 11.48±0.67 13.09±0.74 10.48±0.71 
p value (Control vs Group)   p<0.001 p<0.01 p<0.01 
Total Cholesterol (mmol/l) 
4.92±0.25 5.10±0.19 5.36±0.22 5.54±0.26 
p value (Control vs Group)   p=0.56 p=0.21 p=0.12 
HDL-C (mmo/l) 1.59±0.07 2.46±0.13 1.96±0.09 1.45±0.06 
p value (Control vs Group)   p<0.001 p<0.01 p=0.17 
LDL-C (mmol/l) 3.14±0.22 1.86±0.15 2.92±0.21 3.65±0.24 
p value (Control vs Group)   p<0.001 p=0.49 p=0.15 
Triglyceride (mmol/l) 0.41±0.05 1.71±0.18 1.05±0.05 0.97±0.09 
p value (Control vs Group)   p<0.001 p<0.01 p<0.01 
HDL-C/TC 0.34±0.02 0.48±0.02 0.38±0.02 0.28±0.01 
p value (Control vs Group)   p<0.001 p=0.15 p<005 
LDL-C/HDL-C 2.03±0.14 0.97±0.13 1.65±0.14 2.77±0.23 
p value (Control vs Group)   p<0.001 p=0.084 p<0.05 
MICROALBUMINURIA (mg/l) 14.07±0.90 14.03±1.83 18.03±2.01 33.63±8.03 
p value (Control vs Group)   p<0.001 p=0.146 p=0.06 
SERUM UREA (mmol/l) 4.01±0.24 4.41±0.04 4,83±0.36 7.02±0.64 
p value (Control vs Group)   p<0.001 p=0.11 p<0.01 
SERUM CREATININE (umol/l) 
99.77±5.44 97.27±5.09 214.61±10.36 122.32±13.30 
p value (Control vs Group)   p=0.75 p<0.01 p=0.21 
URINE CREATININE (g/l) 0.94±0.03 0.65±0.05 0.84±0.06 0.51±0.03 
p value (Control vs Group)   p<0.01 p=0.167 p<0.01 
ALBUMIN:CREATININE 15.49±1.27 23.61±2.12 30.56±5.59 65.85±10.38 
p value (Control vs Group)   p<0.01 p=0.042 p<0.01 
   
Tables 3 compared the biochemical characteristics 
among the diabetic subjects. The mean FPG showed an 
increasing trend from the newly diagnosed and to those 
on therapy for 5-10 years but a decrease value among 
those on therapy for over 10 years those on therapy for 
5-10 years had the poorest glycaemic control. 
 
The HBA1c showed a slightly different pattern with the 
group on therapy for over 10 years having the lowest 
mean followed by the newly diagnosed and finally those 
on therapy for 5-10 years. The microalbuminuria 
(measured as microalbumin (mg/L) and albumin in 
mg/g creatinine) showed increasing values from the 
newly diagnosed, to those on therapy for 5-10 years and 
over 10 years.  
In addition, the percentage of subjects who had micro-
albuminuria also increased with increase in disease du-
ration. Microalbuminuria as defined by albumin-to-
creatinine ratio suggested 32% microalbuminuria in the 
newly diagnosed group while mere measurement of 
urinary albumin without comparison with creatinine 
excretion resulted in only 8% microalbuminuria. In 
group C, 60% of the diabetic patients had microalbumi-
nuria by albumin-to-creatinine ratio; but only 32% of 
the same group had microalbuminuria by urine albumin 
alone meaning assessment of microalbuminuria by al-
bumin-to-creatinine ratio is more sensitive.  
 
In Table 4, the correlations between microalbumin and 
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microalbumin, shows significant positive correlation 
with urine creatinine and albumin-to-creatinine ratio (r= 
5.91, p<0.01 and r=14.51, p<0.01respectively). It also 
shows significant negative correlation with triglyceride 
(r=-2.92, p<0.01). In the newly diagnosed diabetics 
(group A), microalbumin has significant positive corre-
lation with serum urea, urine creatinine and albumin-to-
creatinine ratio(r=2.29, p<0.05; r=6.89, p<0.01 and 
r=5.68, <0.01) respectively.  
 
















nosed  (n=50) 
>10 years 




Mean±SEM Mean±SEM   Mean±SEM Mean±SEM   Mean±SEM Mean±SEM   
FPG (mmol/l) 6.53±0.47 7.82±0.47 0.016 7.82±0.47 7.37±0.40 0.480 6.53±0.47 7.37±0.40 0.18 
HBA1C (%) 11.48±0.67 13.09±0.74 0.11 13.09±0.74 10.48±0.71 <0.05 11.48±0.67 10.48±0.71 0.31 
Total Cholesterol 
(mmol/l) 5.10±0.19 5.36±0.22 0.34 5.36±0.22 5.54±0.26 0.61 5.10±0.19 5.54±0.26 0.18 
HDL-C (mmo/l) 2.46±0.13 1.96±0.09 <0.01 1.96±0.09 1.45±0.06 <0.01 2.46±0.13 1.45±0.06 <0.01 
LDL-C (mmol/l) 1.86±0.15 2.92±0.21 <0.01 2.92±0.21 3.65±0.24 <0.05 1.86±0.15 3.65±0.24 <0.01 
Triglyceride 
(mmol/l) 1.71±0.18 1.05±0.05 0.01 1.05±0.05 0.97±0.09 0.46 1.71±0.18 0.97±0.09 <0.01 
HDL-C/TC 0.48±0.02 0.38±0.02 0.001 0.38±0.02 0.28±0.01 <0.01 0.48±0.02 0.28±0.01 <0.01 
LDL-/HDL-C 0.97±0.13 1.65±0.14 <0.01 1.65±0.14 2.77±0.23 <0.01 0.97±0.13 2.77±0.23 <0.01 
MICROALBU-
MINURIA (mg/l) 14.03±1.83 18.03±2.01 0.15 18.03±2.01 33.63±8.03 0.06 14.03±1.83 33.63±8.03 <0.05 
SERUM UREA 




97.27±5.09 214.61±10.4 <0.01 214.61±10.4 122.32±13.3 <0.01 97.27±5.09 122.32±13.3 0.082 
URINE CREAT-




23.61±2.12 30.56±5.59 0.25 30.56±5.59 65.85±10.38 <0.01 23.61±2.12 65.85±10.38 <0.01 
 
In group B microalbumin showed significant positive 
correlation with urine creatinine and albumin-to-
creatinine ratio (r=5.12, p<0.01 and r=14.44, p<0.01) 
respectively and significant negative correlation with 
HBA1c and serum creatinine (r=-2.28, p<0.05 and r= -
2.11, p<0.05) respectively.  
 
Albumin-to-creatinine ratio only had significant positive 
correlation with LDL-C/HDL-C ratio and significant 
negative correlation with serum creatinine (r =2.03, 
p=0.05; r = -2.46, p<0.05 and r = -2.72, p<0.01) respec-
tively in addition to urine creatinine and microalbumin 
in group A; however, in group B, albumin-to-creatinine 
ratio showed significant positive correlations with 
HBA1C and LDL-C/HDL-C ratio while it showed sig-





C(r=2.74, p<0.01; r=4.83, p<0.01; r= -1.99, p<0.05 and 
r= -2.27, p<0.05) respectively. In group C subjects, al-
bumin-to-creatinine ratio had significant positive corre-
lations with HBA1C, total cholesterol and serum urea 
(r=14.76, p<0.001; r=10.13, p<0.001 and r= 10.69, 
p<0.001) while it had significant negative correlations 
with FBG, HDL-C,TG, LDL-C/HDL-C, and serum cre-
atinine ( r=-2.04, p=0.05; r= -10.88, p<0.001; r=-21.06, 
p<0.001; r=-6.73, p<0.001; r=-7.47, p<0.001 and r=-
3.12, p<0.001) respectively.  
 
Using multivariate analysis, the most significant inde-
pendent predictor of ACR among the tested variables 
was disease duration (Odds ratio 2.2, 95% Confidence 
interval CI 1.7-2.8, p< 0.001); then, ethnicity (OR 
0.0001, 95% CI 0.00001-0.001, p=0.002), and level of 
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Table 4 The correlations between albumin: creatinine ratio (ACR) with other measured variables 
Measured Variables 





5-10 Years Dm  
 (N=50) 
 
>10 Years Dm  
 (N=50) 
 
  R P Value R P Value R P Value R P Value 
Microalbuminuria 
Urine Creatinine (G/L) 5.91 <0.01 6.883 <0.001 5.118 <0.01 4.289 <0.01 
Hba1c (%) -0.753 0.462 11.96 0.058 -2.28 0.028 1.301 0.201 
Triglyceride (Mmol/L) -2.924 <0.01 0.018 0.985 1.986 0.055 -1.64 0.109 
Serum Urea (Mmol/L) 0.37 0.716 2.285 0.028 1.324 0.194 0.917 0.365 
Serum Creatinine (Umol/L) 1.442 0.167 1.373 0.178 -2.11 0.042 -0.41 0.683 
Albumin:Creatinine Ratio (Acr) 
Ldl-C/Hdl-C -1.636 0.14 2.034 0.053 4.828 <0.01 -6.73 <0.01 
Serum Creatinine (Umol/L) -0.874 0.408 -2.72 0.012 1.694 0.092 -3.12 <0.01 
Hba1c (%) 0.678 0.517 -0.73 0.47 2.737 <0.01 14.76 <0.01 
Triglyceride (Mmol/L) 0.989 0.352 -1.63 0.116 -1.993 0.048 -21.1 <0.01 
Ldl-C (Mmo/L) 1.343 0.216 -0.87 0.392 -2.271 0.025   Tc   1.329 0.196 -0.266 0.791 10.13 <0.01 Serum Urea (Mmol/L) 0.001 0.999 -1.91 0.068 -1.808 0.073 10.69 <0.01 
Fbg 2.064 0.073 1.302 0.205 -1.361 0.176 -2.04 0.052 
Hdl-C (Mmo/L) -1.289 0.234 -1.15 0.261 1.007 0.316 -10.9 <0.01 
 
Table 5 shows the correlation adjusting for treatment 
modality, comorbidities, gender, age, weight, height, 
BMI, waist circumference, abdominal circumference, 
systolic BP, diastolic BP, occupation, level of educa-
tion, religion, and ethnicity. 
 
 
Table 5 Predictors of ACR in the whole cohort of diabetes patients (n=150) 




OR           (95% CI)                      p* 
Multivariate 
OR     (95% 
CI)              
p** 
Age (years) 14.1          (3.6-57)                      <0.001  
Body weight (Kg) 0.7            (0.2-2.4)                       0.564  
Height (m) 0.0001      (0.00001-0.2)               0.048  
BMI (Kg/m2)   
Waist Circ. 2.2            (0.7- 6.5)                      0.153  
Abdominal Circ. 1.4            (0.4- 4.7)                      0.552 
 
 
Gender   
Systolic BP 1.5            (0.8- 3.0)                      0.199  
Diastolic BP 0.5            (0.2- 1.8)                      0.314  
Comorbidities 10             (1.9-19)                        0.018  
Disease duration 1.9            (1.3- 2.3)                    <0.001 2.2      (1.7-
2.8)          
<0.001 
Treatment Mode 15.7          (7.2- 24.3)                  <0.001  
Occupation 5.5            (1.7- 9.3)                      0.005  
Education Level  0.001   
(0.0001-
0.004)      
0.005  
Ethnicity  0.0001(0.000
01-0.001)     
0.002 
Significance set at ≤0.05; r= correlation coefficient; p = significance of correlation; OR= Odds ratio; 95% CI= 95% Confidence interval; p*= 
significance of association; p**= significance of independent association. 
 
DISCUSSION 
Microalbuminuria, which is highly prevalent in our 
study, is commonly associated with cardiovascular risk 
clustering phenomena.19 This phenomenon also known 
as the metabolic cardiovascular syndrome expresses the 
association between microalbuminuria, dyslipidaemia, 
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sure, left ventricular hypertrophy, and loss of nocturnal 
dip of blood pressure.19  
 
 
Since these risk factors develop on a chronic pattern, 
disease duration would be a common denominator 
among the components. Diabetic nephropathy usually 
develops approximately ten years after the diagnosis of 
type I diabetes and three to five years after the diagnosis 
of type 2 diabetes.20  
 
The interaction of these risk factors as a cause of injury 
to blood vessel may be reliably determined by early 
appearance of microalbumin in the urine, as found in 
our study. This is consistent with the reports of Tabaei 
and Associates.20 
 
Our finding of the mean FPG showing an increasing 
trend from the control subjects to the newly diagnosed, 
those on therapy for 5-10 years but a decrease value 
among those on therapy for over 10 years, implies that 
those on therapy for 5-10 years had the poorest glycae-
mic control. This is corroborated by the glycated hae-
moglobin showing a pattern with the group on therapy 
for over 10 years having the lowest mean followed by 
the newly diagnosed and finally those on therapy for 5-
10 years.  
 
This finding may result from differential compliance 
emanating from relativity of complications, i.e those 
with longest disease duration (>10 years) might have 
better compliance due to experience of more complica-
tions than those with shorter duration (5-10 years). Thus 
our finding is similar to the reports of Samatha P et al21 
that the severity of microvascular complications was 
related to the longer duration of diabetes and the high 
levels of glycosylated haemoglobin.  
 
Similar findings have been observed by Varghese et 
al,22 who reported that the duration of diabetes and reti-
nopathy were the major predictors of microalbuminuria. 
A linear graded relationship has also been observed 
between urine albumin-to-creatinine ratio and cardio-
vascular morbidity and mortality.23 Przegl Lek et al23 
observed that the most important predictor for all forms 
of neuropathy was the duration of diabetes.  
 
In our study, patients with disease duration of more than 
10 years having highest level of microalbuminuria, al-
bumin-to-creatinine ratio and the poorest lipid control 
corroborates the reports that diabetes duration is associ-
ated with onset and progression of nephropathy, 
dyslipidemia and cardiovascular disease risk.20,21 
 
The microalbuminuria (measured as microalbumin 
(mg/L) and albumin-to-creatinine showed increasing 
values from the control group to the newly diagnosed, to 
those on therapy for 5-10 years and over 10 years.  
 
In addition, the percentage of subjects who had micro-
albuminuria also increased with increase in disease du-
ration. Thus, nephropathy progresses with diabetes du-
ration.  
 
This study also showed that albumin-to-creatinine ratio 
reported higher incidence of microalbuminuria in all the 
studied groups than just measuring the urinary microal-
bumin. This is why the ratio of urinary concentrations of 
albumin and creatinine is often used to avoid the re-
quirement (and errors) of collecting a timed urine spec-
imen to calculate the urinary excretion rate of the albu-
min.23,24  
 
The concept underlying this approach is that the rate of 
excretion of creatinine is relatively constant and thus the 
amount excreted reflects the time period of the urine 
collection.23,24 Intra-individual variability for albumin 
excretion rate (AER) is much greater than ACR.24 
Therefore, assessment of microalbuminuria by albumin-
to-creatinine ratio is more sensitive than urine albumin 
alone. 
 
Moreover, the mean systolic BP, LDL-C, LDL-C: HDL-
C ratio, serum urea and albumin-to-creatinine ratio be-
ing significantly higher in patients with DM for over 
10years (with HDL-C, HDL-C: Total cholesterol being 
significantly lower)   than those with duration of 5-10 
years establishes the fact that disease duration is a pre-
dictor of renal and cardiovascular complications and 
thus, of the marker of nephropathy i.e. microalbuminu-
ria.  
 
This is further buttressed by the microalbumin (albu-
min-to-creatinine ratio) showing significant positive 
correlation with FPG, total cholesterol, HBA1C and 
LDL-C/HDL-C ratio, serum urea, urine creatinine and 
systolic blood pressure in the groups on treatment for 5-
10 years and more than 10 years, unlike in the newly 
diagnosed patients in which albumin-to-creatinine ratio 
only had significant positive correlation with LDL-C: 
HDL-C ratio. In summary, albumin-to-creatinine ratio 
exhibited significant correlations with virtually all the 
biochemical variables except HDL-C: Total cholesterol 
with which it had no relationship in all the groups in-
cluding the control group. 
 
CONCLUSION 
In conclusion, the magnitude, progression and severity 
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duration of diabetes and a poor glycemic control in our 
study. Significant relationships exist between ACR and 
other biochemical parameters- HBA1c, TC, HDL-C, 
TG, serum urea and creatinine.  
 
Disease duration, education level, ethnicity, AER, 
HBA1c, TC, TG, HDL-C and LDL/HDL ratio are inde-
pendent predictors of albuminuria.  
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